/
Other
Sleep Disorder
10
Pipeline Programs↗
8
Active Trials↗
5
Companies Involved↗
Sleep Disorder is an early-stage landscape with 10 programs across 5 companies. The most active players are Nanjing Chia-tai Tianqing Pharmaceutical, Supernus Pharmaceuticals, Inc., Sanofi. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 1
No programs
Phase 2
No programs
Phase 32
Approved
No programs
Analysis
Trial Status
42
clinical trials
Completed21 · 50%
Unknown status9 · 21%
Recruiting4 · 10%
Withdrawn3 · 7%
Active, not recruiting2 · 5%
Not yet recruiting1 · 2%
Other2 · 5%
Clinical Trials
Trial Activity
42 trials
Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers in Middle-Aged and Older Adults: A Randomized Controlled Trial
Active, not recruiting·HHuazhong University of Science and Technology·Preclinical·NCT06990256·83 enrolled
Trazodone for Sleep Disorders in Alzheimer's Disease
Completed·—·Phase 3·NCT01142258·40 enrolled
Improving Perioperative Sleep Disorders
Completed·—·Phase 1·NCT06512155·215 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)